
PHARMAXIS INVESTOR R&D SHOWCASE WEBINARS
CLINICIANS TO SPEAK ABOUT PHARMAXIS PROGRAMS

Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) will host R&D showcase webinars for each of the Company's two lead drug discoveries. Presentations by globally renowned clinicians and scientists involved in the Company's clinical programs will be followed by Q&A sessions spearheaded by selected panels of biotech analysts and fund managers.

Pharmaxis drug PXS-5505 targeting several cancers:

Date & time: **29 March 2022 at 11.00am (AEDT)**

Speakers:

- Myelofibrosis - Dr Gabriela Hobbs, Assistant Professor, Medicine, Harvard Medical School & Clinical Director, Leukaemia, Massachusetts General Hospital
- Hepatocellular carcinoma - Dr Paul Burchard, University of Rochester
- Pancreatic cancer - Dr Tom Cox, A/Prof School of Clinical Medicine, UNSW Sydney, Laboratory Head - Matrix and Metastasis, Garvan Institute of Medical Research

To register for this event please use the following link:

https://zoom.us/webinar/register/WN_B8Te020aTUqyb2A3H93saA

Pharmaxis drug PXS-6302 targeting scarring:

Date & time: **31 March 2022 at 11.00am (AEDT)**

Speakers:

- The science of scarring and potential for LOX inhibition - Dr. Mark Fear, Senior Research Fellow University of Western Australia
- Clinical applications for LOX inhibition, unmet need and clinical development strategy - Professor Fiona Wood AM, Director of the Burn Injury Research Unit University of Western Australia

To register for this event please use the following link:

https://zoom.us/webinar/register/WN_66zxZbVsRm-GCocT8_NiAQ

The webinars are free to attend and a recording of the events will be made available on the Pharmaxis website.

#ENDS#

SOURCE: Pharmaxis Ltd, Sydney, Australia

AUTHORISED FOR RELEASE TO ASX BY:

Pharmaxis Ltd Disclosure Committee. Contact: David McGarvey, Chief Financial Officer and Company Secretary: T +61 2 9454 7203, E david.mcgarvey@pharmaxis.com.au

CONTACT:

Media: Felicity Moffatt: T +61 418 677 701, E felicity.moffatt@pharmaxis.com.au

Investor relations: Rudi Michelson (Monsoon Communications) T +61 411 402 737, E rudim@monsoon.com.au

Join the Pharmaxis mailing list [here](#)

Follow us:



About Pharmaxis

Pharmaxis Ltd is an Australian clinical stage drug development company developing drugs for inflammatory and fibrotic diseases, with a focus on myelofibrosis. The company has a highly productive drug discovery engine built on its expertise in the chemistry of amine oxidase inhibitors, with drug candidates in clinical trials. Pharmaxis has also developed two respiratory products which are approved and supplied in global markets, generating ongoing revenue.

Pharmaxis is developing its drug PXS-5505 for the bone marrow cancer myelofibrosis which causes a build up of scar tissue that leads to loss of production of red and white blood cells and platelets. The US Food and Drug Administration has granted Orphan Drug Designation to PXS-5055 for the treatment of myelofibrosis and permission under an Investigational Drug Application (IND) to progress a phase 1c/2 clinical trial that began recruitment in Q1 2021. PXS-5505 is also being investigated as a potential treatment for other cancers such as liver and pancreatic cancer. The FDA has granted an IND for a phase 1c/2a clinical trial in liver cancer.

Other drug candidates being developed from Pharmaxis' amine oxidase chemistry platform are targeting fibrotic diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis; fibrotic scarring from burns and other trauma; and other inflammatory diseases.

Pharmaxis has developed two products from its proprietary spray drying technology that are manufactured and exported from its Sydney facility; Bronchitol® for cystic fibrosis, which is approved and marketed in the United States, Europe, Russia and Australia; and Aridol® for the assessment of asthma, which is approved and marketed in the United States, Europe, Australia and Asia.

Pharmaxis is listed on the Australian Securities Exchange (PXS). Its head office, manufacturing and research facilities are in Sydney, Australia. www.pharmaxis.com.au

Forward-looking statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in developing or partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.